A SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT2) MAY CURE MORE THAN 40% PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Introduction: Relapse of a malignant hematological disease after allogeneic HCT is associated with poor survival and may not be treated with a curative intent. However, a second HCT (HCT2) may achieve durable remission. Objective: To determine the outcomes of pediatric patients who received a HCT2 f...

詳細記述

書誌詳細

出版年:	Hematology, Transfusion and Cell Therapy
主要な著者:	MF Cardoso, G Zamperlini, CNM Breviglieri, R Gouveia, VC Ginani, JF Marques, LL Quintino, LDS Domingues, MGAD Matos, A Seber
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2023-10-01
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2531137923011574